



## **Retrophin to Present at the 2015 Leerink Global Healthcare Conference**

February 5, 2015

SAN DIEGO--(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer of Retrophin, will be presenting at the 2015 Leerink Global Healthcare Conference in New York City on Wednesday, February 11 at 2:40 p.m. ET.

A live webcast will be available at [www.retrophin.com](http://www.retrophin.com) in the Events & Presentations section. A replay of the webcast will be archived on the Retrophin website and accessible for 90 days.

### **About Retrophin**

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Thiola® and Vecamyf®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), schizophrenia, infantile spasms, nephrotic syndrome and others. For additional information, please visit [www.retrophin.com](http://www.retrophin.com).

Retrophin, Inc.  
Chris Cline, CFA  
646-564-3680  
Manager, Investor Relations  
[IR@retrophin.com](mailto:IR@retrophin.com)

Source: Retrophin, Inc.

News Provided by Acquire Media